Jeffrey Lee Boerneke, the General Counsel and Secretary of Aspen Neuroscience, Inc., has filed a report detailing a stock option grant. This filing, submitted on October 29, 2026, is significant as it reflects the company's strategy to incentivize its key personnel.

Aspen Neuroscience, Inc. operates in the pharmaceutical preparations sector, specifically under the SIC classification of 2834. The company is based in San Diego, California, and is incorporated in Delaware. Its fiscal year ends on December 31.

The filing states that Boerneke has been granted stock options that allow him to purchase 101,193 shares of common stock at an exercise price of $9.79 per share. The options will vest gradually, with one-fourth becoming exercisable on May 7, 2027, and the remainder vesting monthly thereafter, contingent on his continued service.

This development may affect Aspen Neuroscience's ability to attract and retain talent in a competitive market, particularly as the pharmaceutical industry continues to evolve. The filing highlights the company's commitment to rewarding its executives and ensuring they are aligned with the company's long-term success.

The filing does not specify any immediate next steps or further actions required following this report.

The stock options granted to Boerneke have an expiration date of May 12, 2036, which provides a long-term incentive for him to contribute to the company's growth and success. This extended time frame allows for strategic planning and execution within the company, aligning Boerneke's interests with those of the shareholders.

Notably, the filing indicates that Boerneke does not currently own any securities in Aspen Neuroscience, which may imply that the stock options represent his first equity stake in the company. This could be seen as a move to further align his interests with those of the shareholders, as he will have a vested interest in the company's performance moving forward.

The filing also confirms that Boerneke is an officer of the company, specifically serving as the General Counsel and Secretary, but he is not a director or a ten percent owner. This distinction highlights his role within the company's management structure and the responsibilities he holds.

While the filing provides detailed information regarding the stock option grant, it does not include any information about Boerneke's previous compensation or any additional equity awards he may have received in the past.